Live Markets News

Loading market data...

markets

This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Yahoo FinanceJune 2, 2026 at 11:53 AM

Read Full Article at Yahoo Finance →

Share:Post Share

Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.

This is a summary. For the full story, read the original article at Yahoo Finance.

Original source: Yahoo Finance

Related Articles

S&P 500 sees $1.8 trillion wipeout, Nasdaq tallies biggest point drop on record: What investors need to know about Friday’s selloff

MarketWatchJune 5, 2026 at 10:27 PM

Here’s what’s worth streaming in June 2026 on Netflix, Hulu, HBO Max and more

MarketWatchJune 5, 2026 at 11:00 PM

‘He’s very short-tempered’: My husband won’t sell his home so we can combine our finances and live in comfort. Am I unreasonable?

MarketWatchJune 6, 2026 at 11:00 AM

← Back to all articles